These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35784328)

  • 1. MIR4435-2HG Is a Potential Pan-Cancer Biomarker for Diagnosis and Prognosis.
    Zhong C; Xie Z; Zeng LH; Yuan C; Duan S
    Front Immunol; 2022; 13():855078. PubMed ID: 35784328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA MIR4435-2HG drives cancer progression by modulating cell cycle regulators and mTOR signaling in stroma-enriched subtypes of urothelial carcinoma of the bladder.
    Pei L; Yan D; He Q; Kong J; Yang M; Ruan H; Lin Q; Huang L; Huang J; Lin T; Qin H
    Cell Oncol (Dordr); 2023 Oct; 46(5):1509-1527. PubMed ID: 37355516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA MIR4435-2HG-mediated upregulation of TGF-β1 promotes migration and proliferation of nonsmall cell lung cancer cells.
    Yang M; He X; Huang X; Wang J; He Y; Wei L
    Environ Toxicol; 2020 May; 35(5):582-590. PubMed ID: 31875359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MIR4435-2HG: A newly proposed lncRNA in human cancer.
    Zhang M; Yu X; Zhang Q; Sun Z; He Y; Guo W
    Biomed Pharmacother; 2022 Jun; 150():112971. PubMed ID: 35447550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA MIR4435-2HG contributes into colorectal cancer development and predicts poor prognosis.
    Shen MY; Zhou GR; -Y Zhang Z
    Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1771-1777. PubMed ID: 32141545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. lncRNA MIR4435-2HG Accelerates the Development of Bladder Cancer through Enhancing IQGAP3 and CDCA5 Expression.
    Yang T; Li Y; Wang G; Guo L; Sun F; Li S; Deng X; Liu J
    Biomed Res Int; 2022; 2022():3858249. PubMed ID: 35993042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MIR4435-2HG: A Tumor-associated Long Non-coding RNA.
    Zhao F; Liu Y; Tan F; Tang L; Du Z; Mou J; Zhou G; Yuan C
    Curr Pharm Des; 2022; 28(25):2043-2051. PubMed ID: 35674305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The lncRNA MIR4435-2HG promotes lung cancer progression by activating β-catenin signalling.
    Qian H; Chen L; Huang J; Wang X; Ma S; Cui F; Luo L; Ling L; Luo K; Zheng G
    J Mol Med (Berl); 2018 Aug; 96(8):753-764. PubMed ID: 29872866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA MIR4435-2HG targets desmoplakin and promotes growth and metastasis of gastric cancer by activating Wnt/β-catenin signaling.
    Wang H; Wu M; Lu Y; He K; Cai X; Yu X; Lu J; Teng L
    Aging (Albany NY); 2019 Sep; 11(17):6657-6673. PubMed ID: 31484163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA MIR4435-2HG functions as a ceRNA against miR-125a-5p and promotes neuroglioma development by upregulating TAZ.
    Shen W; Zhang J; Pan Y; Jin Y
    J Clin Lab Anal; 2021 Dec; 35(12):e24066. PubMed ID: 34714963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA MIR4435-2HG: a key molecule in progression of cancer and non-cancerous disorders.
    Ghasemian M; Rajabibazl M; Sahebi U; Sadeghi S; Maleki R; Hashemnia V; Mirfakhraie R
    Cancer Cell Int; 2022 Jun; 22(1):215. PubMed ID: 35715800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of long non-coding RNA MR4435-2HG suppresses breast cancer progression via the Wnt/β-catenin signaling pathway.
    Chen D; Tang P; Wang Y; Wan F; Long J; Zhou J; Zhuang M; Chen X
    Oncol Lett; 2021 May; 21(5):373. PubMed ID: 33777197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N6-methyladenosine-modified oncofetal lncRNA MIR4435-2HG contributed to stemness features of hepatocellular carcinoma cells by regulating rRNA 2'-O methylation.
    Zhu Y; Xiao B; Liu M; Chen M; Xia N; Guo H; Huang J; Liu Z; Wang F
    Cell Mol Biol Lett; 2023 Oct; 28(1):89. PubMed ID: 37891494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA MIR4435-2HG is a potential early diagnostic marker for ovarian carcinoma.
    Gong J; Xu X; Zhang X; Zhou Y
    Acta Biochim Biophys Sin (Shanghai); 2019 Sep; 51(9):953-959. PubMed ID: 31435668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long Noncoding RNA MIR4435-2HG Suppresses Colorectal Cancer Initiation and Progression By Reprogramming Neutrophils.
    Yu H; Chen C; Han F; Tang J; Deng M; Niu Y; Lai M; Zhang H
    Cancer Immunol Res; 2022 Sep; 10(9):1095-1110. PubMed ID: 35862232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA MIR4435-2HG mediates cisplatin resistance in HCT116 cells by regulating Nrf2 and HO-1.
    Luo P; Wu S; Ji K; Yuan X; Li H; Chen J; Tian Y; Qiu Y; Zhong X
    PLoS One; 2020; 15(11):e0223035. PubMed ID: 33232319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNA MIR4435-2HG recruits miR-802 from FLOT2 to promote melanoma progression.
    Ma DM; Sun D; Wang J; Jin DH; Li Y; Han YE
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2616-2624. PubMed ID: 32196611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA MIR4435-2HG potentiates the proliferation and invasion of glioblastoma cells via modulating miR-1224-5p/TGFBR2 axis.
    Xu H; Zhang B; Yang Y; Li Z; Zhao P; Wu W; Zhang H; Mao J
    J Cell Mol Med; 2020 Jun; 24(11):6362-6372. PubMed ID: 32319715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic stellate cell-released CXCL1 aggravates HCC malignant behaviors through the MIR4435-2HG/miR-506-3p/TGFB1 axis.
    Li S; Hu X; Yu S; Yi P; Chen R; Huang Z; Huang Y; Huang Y; Zhou R; Fan X
    Cancer Sci; 2023 Feb; 114(2):504-520. PubMed ID: 36169092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA MIR4435-2HG predicts poor prognosis in patients with colorectal cancer.
    Ouyang W; Ren L; Liu G; Chi X; Wei H
    PeerJ; 2019; 7():e6683. PubMed ID: 30972258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.